-
-
-
-
-
-
-
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
-
-
-
-
-
-
-
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) to offer 3.64M Shares of Class A common stock directly to certain institutional investors
-
-
-
-
-
-
-
vTv Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2015
51,662 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All